Steinberg BA, Deering TF, Holubkov R, et al. Expedited Loading with Intravenous Sotalol and Mobile ECG Monitoring – Primary Results of the Prospective Evaluation Analysis and Kinetics of IV Sotalol (PEAKS) Registry. Poster Presented at Heart Rhythm Society 2023; May 19 -21, 2023; New Orleans, LA.
In their poster presented at the Heart Rhythm Society 2023 meeting in New Orleans, Dr. Steinberg et al provided an overview of the results of the PEAKS Sotalol IV registry. In that multicenter, prospective evaluation of 151 patients, which included pharmacokinetics / pharmacodynamics profiles and mobile ECG monitoring, the mean length of stay was 0.8 days. Sotalol IV was viewed as safe and feasible, with low rates of adverse events and shortened length of hospitalization.
